Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 7/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.61 |
| ▸ | HPGD | P15428 | 3/20 | 0.61 |
| ▸ | NPC1 | O15118 | 1/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.61 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.61 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.61 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.61 |
| ▸ | RAB9A | P51151 | 1/20 | 0.61 |
| ▸ | LMNA | P02545 | 5/20 | 0.55 |
| ▸ | HTT | P42858 | 2/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.49 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.49 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | DRD4 | P21917 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29897293 | 1.00 | MAPT (0.61) | MAPTSMN1; SMN2HPGDNPC1CYP1A2 | |
| SCHEMBL5099839 | 0.94 | MAPT (0.65) | MAPTSMN1; SMN2HPGDNPC1CYP1A2 | |
| SCHEMBL30907664 | 0.94 | MAPT (0.65) | MAPTSMN1; SMN2HPGDNPC1CYP1A2 | |
| SCHEMBL2086989 | 0.94 | MAPT (0.61) | MAPTSMN1; SMN2HPGDNPC1CYP1A2 | |
| SCHEMBL9220403 | 0.91 | MAPT (0.52) | MAPTSMN1; SMN2HPGDNPC1CYP1A2 | |
| SCHEMBL4038925 | 0.88 | MAPT (0.65) | MAPTSMN1; SMN2HPGDNPC1CYP1A2 | |
| SCHEMBL4045709 | 0.87 | MAPT (0.64) | MAPTSMN1; SMN2HPGDNPC1CYP1A2 | |
| SCHEMBL7416033 | 0.86 | CYP19A1 (0.59) | MAPTSMN1; SMN2HPGDNPC1CYP1A2 | |
| SCHEMBL6431028 | 0.86 | MAPT (0.59) | MAPTSMN1; SMN2HPGDNPC1CYP1A2 | |
| SCHEMBL8240311 | 0.85 | MAPT (0.65) | MAPTSMN1; SMN2HPGDNPC1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110698389-B | N- [2- (2-methoxy-5-nitro-phenoxy) ethyl ] halogenated pyridine and preparation method and application thereof | 河南省科学院高新技术研究中心 | 2022-10-04 | — | — | CN | disclosed |
| CN-110698389-A | N- [2- (2-methoxy-5-nitro-phenoxy) ethyl ] halogenated pyridine and preparation method and application thereof | 河南省科学院高新技术研究中心 | 2020-01-17 | — | — | CN | disclosed |
| EP-2247294-B1 | MACROLIDES FOR TREATING DISEASES MEDIATED THROUGH PDE INHIBITION | BASILEA PHARMACEUTICA AG (CH) | 2014-03-26 | — | — | EP | disclosed |
| US-8445451-B2 | Macrolides and uses of macrolides | BASILEA PHARMACEUTICA AG (CH) | 2013-05-21 | — | — | US | disclosed |
| US-20110021449-A1 | MACROLIDES AND USES OF MACROLIDES | BASILEA PHARMACEUTICA AG (CH) | 2011-01-27 | — | — | US | disclosed |
| EP-2247294-A2 | MACROLIDES FOR TREATING DISEASES MEDIATED THROUGH PDE INHIBITION | Basilea Pharmaceutica AG (CH) | 2010-11-10 | — | — | EP | disclosed |
| WO-2009098320-A2 | MACROLIDES AND USES OF MACROLIDES | BASILEA PHARMACEUTICA AG (CH) | 2009-08-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110021449-A1 | MACROLIDES AND USES OF MACROLIDES | MRPS22, MRPS23, MRPL12 | MAPT 4802/4885SMN1; SMN2 2417/4885HPGD 3396/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.